Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.510
-0.050 (-3.21%)
At close: May 5, 2026, 4:00 PM EDT
1.550
+0.040 (2.65%)
After-hours: May 5, 2026, 7:33 PM EDT
Marker Therapeutics Employees
Marker Therapeutics had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$709,334
Profits / Employee
-$2,432,724
Market Cap
25.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | -59 | -88.06% |
| Dec 31, 2022 | 67 | 11 | 19.64% |
| Dec 31, 2021 | 56 | 12 | 27.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Vistagen Therapeutics | 59 |
| Longeveron | 38 |
| Curis | 24 |
| Jasper Therapeutics | 22 |
| ABVC BioPharma | 19 |
| Outlook Therapeutics | 17 |
| Lantern Pharma | 16 |
MRKR News
- 6 weeks ago - Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewsWire
- 2 months ago - Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer - GlobeNewsWire
- 6 months ago - Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors - GlobeNewsWire
- 6 months ago - Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting - GlobeNewsWire
- 7 months ago - Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program - GlobeNewsWire